Immix Bio soars on positive data from cancer drug animal study

Immix Biopharma

12/01/2022 18:31

** Shares of drug developer  IMMX.O  soar 22% to $6.63 in
afternoon trading  
    ** IMMX says its drug candidate, IMX-110, led to cancer
reduction in 50% of mice with soft tissue sarcoma that had
failed prior treatment in a study  urn:newsml:reuters.com:*:nGNX1qTKXy
    ** Soft tissue sarcomas are cancers that develop in soft
tissues such as fat, muscle, nerves and can be found in any part
of the body
    ** Company says IMX-110 surpassed effectiveness of the
standard-of-care treatment, which produced a response rate of 0%
in the same study
    ** ~160,000 people live with soft tissue cancers in the
United States, according to co
    ** IMMX is also developing the drug for the treatment of
rhabdomyosarcoma, a life-threatening form of cancer in children
    ** Including session's gains, stock up 32.6% since December
IPO

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))